NEW YORK – Exai Bio, a company recently spun out of the University of California San Francisco based on work in the lab of Hani Goodarzi, is working to develop blood-based tests for cancer early detection and potentially other applications, enabled by genome-wide analysis of small non-coding RNAs.
Formed about six months ago and funded by a $67.5 million Series A financing last Decem…….